- 著者
- Makoto Kinoshita Koutaro Yokote Hidenori Arai Mami Iida Yasushi Ishigaki Shun Ishibashi Seiji Umemoto Genshi Egusa Hirotoshi Ohmura Tomonori Okamura Shinji Kihara Shinji Koba Isao Saito Tetsuo Shoji Hiroyuki Daida Kazuhisa Tsukamoto Juno Deguchi Seitaro Dohi Kazushige Dobashi Hirotoshi Hamaguchi Masumi Hara Takafumi Hiro Sadatoshi Biro Yoshio Fujioka Chizuko Maruyama Yoshihiro Miyamoto Yoshitaka Murakami Masayuki Yokode Hiroshi Yoshida Hiromi Rakugi Akihiko Wakatsuki Shizuya Yamashita Committee for Epidemiology and Clinical Management of Atherosclerosis
- 出版者
- Japan Atherosclerosis Society
- 雑誌
- Journal of Atherosclerosis and Thrombosis (ISSN:13403478)
- 巻号頁・発行日
- vol.25, no.9, pp.846-984, 2018-09-01 (Released:2018-09-01)
- 参考文献数
- 999
- 被引用文献数
- 347 534
2 0 0 0 OA Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis
- 著者
- Hiroyuki Ariyasu Hiroshi Iwakura Naoichiro Yukawa Toshinori Murayama Masayuki Yokode Harue Tada Kenichi Yoshimura Satoshi Teramukai Tatsuya Ito Akira Shimizu Atsushi Yonezawa Kenji Kangawa Tsuneyo Mimori Takashi Akamizu
- 出版者
- (社)日本内分泌学会
- 雑誌
- Endocrine Journal (ISSN:09188959)
- 巻号頁・発行日
- pp.EJ14-0088, (Released:2014-04-17)
- 被引用文献数
- 6 20
The majority of patients with systemic sclerosis (SSc) have gastrointestinal (GI) tract involvement, but therapies using prokinetic agents are usually unsatisfactory. Ghrelin stimulates gastric motility in healthy human volunteers. In this study, we investigated whether ghrelin could improve gastric emptying in patients with gastrointestinal symptoms due to SSc. The study was performed in a randomized, double-blind, placebo-controlled crossover fashion on two occasions. Ten SSc patients with GI tract involvement received an infusion of either ghrelin (5.0 μg/kg) or saline, and gastric emptying rate was evaluated by 13C-acetic acid breath test. Gastric emptying was significantly accelerated by ghrelin infusion in patients with SSc (ghrelin vs. saline: 43.3 ± 11.4 min vs. 53.4 ± 5.4 min, P≡0.03). No serious adverse effects were observed. Our results suggest that ghrelin might represent a new therapeutic approach for GI tract involvement in patients with SSc.